Polycomb protein family member CBX7 plays a critical role in cancer progression.

CBX7 is a polycomb protein that participates in the formation of polycomb repressive complex 1. Apart from few exceptions, CBX7 expression is lost in human malignant neoplasias and a clear correlation between its downregulated expression and a cancer aggressiveness and poor prognosis has been observed. These findings indicate a critical role of CBX7 in cancer progression. Consistently, CBX7 is able to differentially regulate crucial genes involved in cancer progression and in epithelial-mesenchymal transition, as osteopontin and E-cadherin. Recent evidences indicate a role of CBX7 also in the modulation of response to therapy. In conclusion, CBX7 represents an important prognostic factor, whose loss of expression in general indicates a bad prognosis and a progression towards a fully malignant phenotype.

[1]  K. Miller,et al.  Expression Parameters of the Polycomb Group Proteins BMI1, SUZ12, RING1 and CBX7 in Urothelial Carcinoma of the Bladder and Their Prognostic Relevance , 2008, Tumor Biology.

[2]  A. Fusco,et al.  The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. , 2010, European journal of cancer.

[3]  Chris T. A. Evelo,et al.  Presenting and exploring biological pathways with PathVisio , 2008, BMC Bioinformatics.

[4]  Zhen Jiang,et al.  Increased expression of miR-421 in human gastric carcinoma and its clinical association , 2009, Journal of Gastroenterology.

[5]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[6]  A. Fusco,et al.  CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation , 2014, Biology Open.

[7]  G. Viglietto,et al.  High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases , 2001, International journal of cancer.

[8]  T. Jenuwein,et al.  Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. , 2007, Cancer cell.

[9]  D. Beach,et al.  Polycomb CBX7 has a unifying role in cellular lifespan , 2004, Nature Cell Biology.

[10]  A. Fusco,et al.  Deregulation of microRNA expression in thyroid neoplasias , 2014, Nature Reviews Endocrinology.

[11]  Giancarlo Troncone,et al.  Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. , 2010, Genes & cancer.

[12]  G. Mælandsmo,et al.  Osteopontin—An important downstream effector of S100A4‐mediated invasion and metastasis , 2011, International journal of cancer.

[13]  A. Fusco,et al.  CBX7 Modulates the Expression of Genes Critical for Cancer Progression , 2014, PloS one.

[14]  Vincenza Leone,et al.  Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. , 2009, Cancer research.

[15]  G. Chiappetta,et al.  CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas) , 2014, European Thyroid Journal.

[16]  A. Chambers,et al.  Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management , 2007, Journal of cellular biochemistry.

[17]  S. Lowe,et al.  Role of the chromobox protein CBX7 in lymphomagenesis , 2007, Proceedings of the National Academy of Sciences.

[18]  M. Santoro,et al.  Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. , 2008, Cancer research.

[19]  A. Fusco,et al.  CBX7 is a tumor suppressor in mice and humans , 2012 .

[20]  G. Crabtree,et al.  Understanding the Words of Chromatin Regulation , 2009, Cell.

[21]  Frank Speleman,et al.  miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis , 2010, Nature Cell Biology.

[22]  M. Begemann,et al.  Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective , 2007, Stem cells.

[23]  K. Matušan,et al.  Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma , 2006, Journal of surgical oncology.

[24]  Takashi Takahashi,et al.  Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL‐induced apoptotic pathway regulation , 2014, International journal of cancer.

[25]  A. Fusco,et al.  CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression , 2015, Oncotarget.

[26]  Y. Gong,et al.  [MiR-9 regulates the expression of CBX7 in human glioma]. , 2008, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[27]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[28]  Daniel Chourrout,et al.  Genome Regulation by Polycomb and Trithorax Proteins , 2007, Cell.

[29]  Y. Atomi,et al.  Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. , 1999, Cancer research.

[30]  A. Fusco,et al.  Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. , 2010, European journal of cancer.

[31]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[32]  R. Rosenberg,et al.  Expression of osteopontin, a target gene of de‐regulated Wnt signaling, predicts survival in colon cancer , 2007, International journal of cancer.

[33]  A. Fusco,et al.  Roles of HMGA proteins in cancer , 2007, Nature Reviews Cancer.

[34]  David Beach,et al.  CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus , 2005, Oncogene.

[35]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[36]  Rahul Jandial,et al.  Altered Expression of Polycomb Group Genes in Glioblastoma Multiforme , 2013, PloS one.

[37]  Jining Lu,et al.  Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer , 2011, Breast Cancer Research.

[38]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.